Doug Crawford, PhD is a Managing General Partner at Mission BioCapital in the San Francisco office. He focuses on seed and early stage biopharmaceutical investments as well as overall management of the firm. He currently holds board roles at Alessa Therapeutics, Avexegen Therapeutics, Epiodyne, Graphwear Technologies, Invenio, Magnamosis, Magnap, Mitokinin, SiteOne, and Tangible Science. Doug also runs Mission BioCapital’s labs in the Bay Area, MBC BioLabs. Doug has made over 40 other investments in the Mission BioCapital portfolio including Alector Therapeutics, Caribou, Cell Design Labs, eFFECTOR, iPierian, Principia Biopharma, Redwood BioSciences, and Zymergen. Doug has been helping entrepreneurial scientists launch biotech startups since 2004. He created the first technical incubator for the University of California system while an associate director of QB3. This initiative demonstrated a new and better way to launch life-science startups. Based on that success Doug founded Mission Bay Capital, a predecessor to Mission BioCapital. In 2013, he created the first of 5 co-working labs for MBC BioLabs. These Bay Area labs allow companies with nothing more than a dream and a credit card to become a viable biotech company. They have been home to 240 companies that have brought 88 drug programs to the clinic, 71 therapeutic products to market, and raised over $10 billion. Doug received his PhD in biochemistry from UCSF where he studied the regulation of aging.